Izimpawu Zokusebenza
Umkhawulo Wokuthola: 5ng/mL;
Ububanzi Bomugqa: 5.00～400.00 ng/mL;
I-coefficient yokuhlobana komugqa R ≥0.990;
Ukunemba: ngaphakathi kweqoqo le-CV ngu-≤15%;phakathi kwamaqoqo i-CV ingu-≤20%;
Ukunemba: ukuchezuka okuhlobene kwemiphumela yokulinganisa akumele kudlule ku-±15% lapho isilinganisi sokunemba esimisiwe sihlolwa.
1. Gcina ibhafa yomtshina ku-2～30℃.Isigcinalwazi sizinzile kufika ezinyangeni eziyi-18.
2. Gcina ikhasethi le-Aehealth Ferritin Rapid Quantitative test ku-2～30℃, impilo yeshalofu ifinyelela ezinyangeni eziyi-18.
3. Ikhasethi lokuhlola kufanele lisetshenziswe phakathi nehora elingu-1 ngemva kokuvula iphakethe.
I-ST2 iyilungu le-Toll-like receptor/interleukin-1 (interleukin-1, IL-1) superfamily receptor.I-IL-33 iyi-ligand yayo ethile esebenzayo futhi ikhiqizwa ama-cardiomyocytes nama-fibroblasts.Imikhiqizo emibili ye-gene expression: transmembrane ST2 (ST2L) kanye ne-sST2.I-ST2L iqukethe izizinda ezintathu ze-extracellular immunoglobulin, kuyilapho i-sST2 ingenayo isizinda se-transmembrane kanye ne-intracellular receptor.Zibophezela ku-ligand evamile IL-33 futhi zidlala indima yezinto eziphilayo.I-ST2L ne-IL-33 indlela yokusayina inemiphumela ye-cardiomyocyte efana ne-anti-cardiomyocyte hypertrophy, i-myocardial fibrosis kanye ne-anti-atherosclerosis.Uma umthwalo wenhliziyo ukhula, ukukhishwa kwe-sST2 kuyanda, futhi i-sST2 eyandayo ivimbela i-IL-33 ukuthi ihlangane ne-ST2L, ngaleyo ndlela imelana nomphumela we-cardioprotective we-IL-33/ST2L indlela yokusayina.Kucatshangwa ukuthi i-sST2 ingase ibe umlamuleli we-pathogenic we-cardiomyocyte hypertrophy kanye ne-myocardial fibrosis.Ukunqunywa okulinganiselwe kwamazinga e-sST2 kunganikeza odokotela ithuluzi elinembile lokusiza ekuhloleni ukwehluleka kwenhliziyo.